Continued success leads to PDS Expansion

Date posted: October 17, 2016

PDS is a partner of choice for many life sciences companies requiring outsourced pharmacovigilance and regulatory services. As part of its continued growth, PDS is delighted to announce the opening of its new satellite office at BioCity Nottingham.

Opening the Nottingham office brings PDS closer together with the Biotech community, allowing the company to better serve its clients with outsourced Pharmacovigilance services for Clinical Trials. In recent years this has become a key area of growth and so being more accessible to the Biotech community is a logical step. In addition, PDS will be holding a range of events and seminars at the Nottingham site, whilst also creating a world class, state-of-the-art facility for hosting clients and partners.

Looking forward, PDS aims to build on and strengthen its existing partnerships within the Biotech community and to develop new ones. BioCity is very much a hub for innovation, which will undoubtedly foster sustainable growth and development for partner companies within the network. Additionally, established links with the Biotech communities in the north of England and Scotland, provides a strong network of life-science companies driving innovation throughout the UK.

Whilst PDS would never lay claim to being innovative by comparison, it does support this innovation through its vast experience and knowledge of PV in Clinical Trials. Acting as a key drug safety partner, PDS helps Biotech companies remain compliant throughout the clinical development phase, provides invaluable support towards gaining approval to market a product and in post market surveillance.

Finally, a boasted 91% survival rate of companies based at BioCity in Nottingham demonstrates the tangible benefits of being located within the BioCity network. As a respected provider of pharmacovigilance and regulatory services, PDS is in a position to help sustain such high success rates through providing practicable advice and professional services to the Biotech community.

Carol Kingstone, Managing Director at PDS commented, “These are hugely exciting times for PDS and we are delighted to be in a position to work more closely with the Biotech community through providing critical pharmacovigilance and regulatory services to support its growth.

‘With our TEAM focused, partnership approach, we look forward to developing high value and mutually beneficial relationships in the coming years, and to contributing to the success of the UK Biotech industry.’

For further information about PDS please visit puredrugsafety.com.

JOIN US

SIGN IN

JOIN

LOGIN

Latest Opportunities

The Open University Mentoring Opportunity

Mental Health First Aid training offer for the Medilink Midlands network

Office for Life Sciences Bulletin – 4 December 2025

Latest News

New pilot programme launches to address life sciences skills gap across Midlands and East of England

IC26 is here, and it’s bigger than ever!

Join 3P innovation and ISPE UK Affiliate for the UK Pharmaceutical & MedTech Innovations event

To register for this event, please complete the form below.

Company Information

Delegate Information

Delegate One

Delegate Two

Delegate Three

Delegate Four

Delegate Five

Delegate Six

Delegate Seven

Delegate Eight

Delegate Nine

Delegate Ten

Terms and Conditions

In order to complete this booking, you must accept our standard terms and conditions, which can be viewed here (opens in new window). Please note that these contain important information which you are advised to read before accepting.

Please check this box to accept Medilink’s Event Booking Terms and Conditions (*):

To register for this event, please complete the form below.

Company Information

Delegate Information

Delegate One

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Delegate Two

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Delegate Three

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Delegate Four

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Delegate Five

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Delegate Six

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Delegate Seven

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Delegate Eight

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Delegate Nine

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Delegate Ten

This event is being subsidised with public funds from the European Regional Development Fund. If public funding was not available we would have to charge a commercial rate for attendance. If that were the case, would this affect your decision to attend?

Terms and Conditions

In order to complete this booking, you must accept our standard terms and conditions, which can be viewed here (opens in new window). Please note that these contain important information which you are advised to read before accepting.

Please check this box to accept Medilink’s Event Booking Terms and Conditions (*):

Your innovation deserves recognition

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You​

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You

Almost There! Just Tell Us a Bit About You